Citations

Mayo Clinic

Showing 10 of 108537 citations.

Pulmonary Hypertension and Anastrozole (PHANTOM): A Randomized, Double-Blind, Placebo-Controlled Trial
Kawut, Steven M. , Feng, Rui , Ellenberg, Susan S. , Zamanian, Roham T. , Bull, Todd M., Chakinala, Murali M. , Mathai, Stephen C. , Hemnes, Anna R. , Lin, Grace , Andrew, Ruth , Stasinopoulos, Ioannis , Shou, Haochang , Song, Nianfu, Moutchia, Jude , Hemnes, Anna , Austin, Eric , Minhas, Jasleen , Ventetuolo, Corey E , Kawut, Steven M , Mathai, Stephen C , Doyle, Margaret F. , MacLean, Margaret R. , DeMichele, Angela , Minhas, Jasleen , Song, Nianfu, Ventetuolo, Corey E.

American Journal of Respiratory and Critical Care Medicine | May 15, 2024 | Volume: 210 | Issue: 9 | Pages: 1143-1151

10.1164/rccm.202402-0371oc | PMID 38747680 Get It

Abstract Rationale Inhibition of aromatase with anastrozole reduces pulmonary hypertension in experimental models. Objectives We aimed to determine whether anastrozole improved the 6-minute-walk distance (6MWD) at 6 months in pulmonary arterial hypertension (PAH). Methods We performed a randomized, double-blind, placebo-controlled phase II clinical trial of anastrozole in subjects with PAH at seven centers. Eighty-four postmenopausal women with PAH and men with PAH were randomized in a 1:1 ratio to receive anastrozole 1 mg or placebo by mouth daily, stratified by sex using permuted blocks of variable sizes. All subjects and study staff were masked. The primary outcome was the change from baseline in 6MWD at 6 months. By intention-to-treat analysis, we estimated the treatment effect of anastrozole using linear regression models adjusted for sex and baseline 6MWD. Assuming 10% loss to follow-up, we anticipated having 80% power to detect a difference in the change in 6MWD of 22 meters. Measurements and Main Results Forty-one subjects were randomized to placebo and 43 to anastrozole, and all received the allocated treatment. Three subjects in the placebo group and two in the anastrozole group discontinued the study drug. There was no significant difference in the change in 6MWD at 6 months (placebo-corrected treatment effect, −7.9 m; 95% confidence interval, −32.7 to 16.9; P = 0.53). There was no difference in adverse events between the groups. Conclusions Anastrozole did not show a significant effect on 6MWD compared with placebo in postmenopausal women with PAH and in men with PAH. Anastrozole was safe and did not have adverse effects. Clinical trial registered with www.clincialtrials.gov (NCT03229499).
Three‐dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma
Kumar, Shaji , Rajkumar, S. Vincent , Jevremović, Dragan , Kyle, Robert A. , Shifrin, Yulia , Nguyen, Michelle , Husain, Zahabiya, Alikhah, Asieh, Jafari, Anita, Louis, Sherif, Rajkumar, S Vincent , Jevremovic, Dragan , Mai, Sabine , Anderson, Kenneth C.

American Journal of Hematology | May 15, 2024 | Volume: 99 | Issue: 8 | Pages: 1532-1539

10.1002/ajh.27364 | PMID 38747543 Get It

AbstractSmoldering multiple myeloma (SMM) is a precursor stage that precedes multiple myeloma (MM). SMM is heterogenous with nearly 40% of patients progressing to MM in the first 5 years. The high rate of progression of SMM patients highlights the need for early intervention, which underscores the importance of identifying SMM patients with the highest risk of progression. Several risk stratification models showed utility in identifying high‐risk SMM patients; however, these systems showed limited sensitivity. To date, identifying high‐risk SMM patients remains an important clinical need. In this study, we present the 3‐dimensional telomere profiling as a structural biomarker capable of stratifying SMM patients as a function of genomic instability. Quantifying telomere dysfunction using the TeloView technology showed utility in risk stratification of cancer patients, particularly hematological malignancies. In this study, we analyzed 168 SMM patients. We report an AUC in ROC analysis of 0.8 using a subset of the patients as a training dataset. We then conducted a blind validation on a different cohort and demonstrated a positive predictive value of 85% and negative predictive value of 73%, with sensitivity and specificity of 83% and 76%, respectively. We examined the correlation between the TeloView prediction and the 20‐2‐20 scoring system, and cytogenetic abnormalities. We report a correlation of 53% with the 20‐2‐20 scores and over 60% correlation with cytogenetic abnormalities. The result of this study presents the telomere profiling as an effective biomarker able to stratify SMM patients to their respective risk groups with high sensitivity and specificity.
Association of 24-h central hemodynamics and stiffness with cardiovascular events and all-cause mortality. The VASOTENS Registry
Omboni, Stefano , Alfie, José , Arystan, Ayana, Avolio, Alberto , Barin, Edward , Bokusheva, Jamilya, Bulanova, N , Butlin, Mark , Cuffaro, Paula E. , Derevyanchenko, M. V. , Grigoricheva, Elena, Gurevich, A. , Paini, Anna, Pereira, Telmo , Tan, Isabella , Group, the VASOTENS Registry Study, Arystan, Ayana, Конради, А. О. , Muiesan, María Lorenza , Стаценко, Михаил Евгеньевич , Group, the VASOTENS Registry Study

Journal of Hypertension | May 15, 2024 | Volume: 42 | Issue: 9 | Pages: 1590-1597

10.1097/hjh.0000000000003763 | PMID 38747378 Get It

Objectives: In hemodialysis patients, central hemodynamics, stiffness, and wave reflections assessed through ambulatory blood pressure monitoring (ABPM) showed superior prognostic value for cardiovascular (CV) events than peripheral blood pressures (BPs). No such evidence is available for lower-risk hypertensive patients. Methods: In 591 hypertensive patients (mean age 58 ± 14 years, 49% males), ambulatory brachial and central BP, pulse wave velocity (PWV), and augmentation index (AIx) were obtained with a validated upper arm cuff-based pulse wave analysis technology. Information on treatment for hypertension (73% of patients), dyslipidemia (27%), diabetes (8%), CV disease history (25%), was collected. Patients were censored for CV events or all-cause death over 4.2 years. Results: One hundred and four events (24 fatal) were recorded. Advanced age [hazard ratio and 95% confidence interval: 1.03 (1.01, 1.05), P = 0.0001], female sex [1.57 (1.05, 2.33), P = 0.027], CV disease [2.22 (1.50, 3.29), P = 0.0001], increased 24-h central pulse pressure (PP) [1.56 (1.05, 2.31), P = 0.027], PWV [1.59 (1.07, 2.36), P = 0.022], or AIx [1.59 (1.08, 2.36), P = 0.020] were significantly associated with a worse prognosis (univariate Cox regression analysis). The prognostic power of peripheral and central BPs was lower. However, PWV [1.02 (0.64, 1.63), P = 0.924], AIx [1.06 (0.66, 1.69), P = 0.823], and central PP [1.18 (0.76, 1.82), P = 0.471], were not significant predictors in multivariate analyses. Conclusions: In hypertensive patients, ambulatory central PP, PWV, and AIx are associated with an increased risk of CV morbidity and all-cause mortality. However, this association is not independent of other patient characteristics.
Circulating Tumor DNA as a Complementary Prognostic Biomarker during CAR-T Therapy in B-Cell Non-Hodgkin Lymphomas
Monick, Sarah, Rosenthal, Allison

Cancers | May 15, 2024 | Volume: 16 | Issue: 10 | Pages: 1881

10.3390/cancers16101881 | PMID 38791959 Get It

The emergence of CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment paradigm for R/R B-cell NHLs. However, challenges persist in accurately evaluating treatment response and detecting early relapse, necessitating the exploration of novel biomarkers. Circulating tumor DNA (ctDNA) via liquid biopsy is a non-invasive tool for monitoring therapy efficacy and predicting treatment outcomes in B-NHL following CAR-T therapy. By overcoming the limitations of conventional imaging modalities, ctDNA assessments offer valuable insights into response dynamics, molecular mechanisms of resistance, and early detection of molecular relapse. Integration of ctDNA monitoring into clinical practice holds promise for personalized therapeutic strategies, guiding the development of novel targeted therapies, and enhancing patient outcomes. However, standardization of assay methodologies and consensus on clinical response metrics are imperative to unlock the full potential of ctDNA in the management of B-NHL. Prospective validation of ctDNA in clinical trials is necessary to establish its role as a complementary decision aid.
Guidelines for Reasonable and Appropriate Care in the Emergency Department (GRACE‐4): Alcohol use disorder and cannabinoid hyperemesis syndrome management in the emergency department
Borgundvaag, Bjug , Bellolio, Fernanda , Miles, Isabelle , Schwarz, Evan S. , Sharif, Sameer , Baumgartner, Kevin , Austin, Emily , Upadhye, Suneel , Klaiman, Michelle , Vellend, Robert, Munkley, Anna, Su, Mark K , Baumgartner, Kevin , Liss, David B , Sheikh, Hasan , Vogel, Jody , Austin, Emily B , Upadhye, Suneel , Klaiman, Michelle , Carpenter, Christopher R , Bellolio, M Fernanda , Vogel, Jody A. , Carpenter, Christopher R.

Academic Emergency Medicine | May 15, 2024 | Volume: 31 | Issue: 5 | Pages: 425-455

10.1111/acem.14911 | PMID 38747203 Get It

Abstract The fourth Society for Academic Emergency Medicine (SAEM) Guidelines for Reasonable and Appropriate Care in the Emergency Department (GRACE‐4) is on the topic of the emergency department (ED) management of nonopioid use disorders and focuses on alcohol withdrawal syndrome (AWS), alcohol use disorder (AUD), and cannabinoid hyperemesis syndrome (CHS). The SAEM GRACE‐4 Writing Team, composed of emergency physicians and experts in addiction medicine and patients with lived experience, applied the Grading of Recommendations Assessment Development and Evaluation (GRADE) approach to assess the certainty of evidence and strength of recommendations regarding six priority questions for adult ED patients with AWS, AUD, and CHS. The SAEM GRACE‐4 Writing Team reached the following recommendations: (1) in adult ED patients (over the age of 18) with moderate to severe AWS who are being admitted to hospital, we suggest using phenobarbital in addition to benzodiazepines compared to using benzodiazepines alone [ low to very low certainty of evidence ]; (2) in adult ED patients (over the age of 18) with AUD who desire alcohol cessation, we suggest a prescription for one anticraving medication [ very low certainty of evidence ]; (2a) in adult ED patients (over the age of 18) with AUD, we suggest naltrexone (compared to no prescription) to prevent return to heavy drinking [ low certainty of evidence ]; (2b) in adult ED patients (over the age of 18) with AUD and contraindications to naltrexone, we suggest acamprosate (compared to no prescription) to prevent return to heavy drinking and/or to reduce heavy drinking [ low certainty of evidence ]; (2c) in adult ED patients (over the age of 18) with AUD, we suggest gabapentin (compared to no prescription) for the management of AUD to reduce heavy drinking days and improve alcohol withdrawal symptoms [ very low certainty of evidence ]; (3a) in adult ED patients (over the age of 18) presenting to the ED with CHS we suggest the use of haloperidol or droperidol (in addition to usual care/serotonin antagonists, e.g., ondansetron) to help with symptom management [ very low certainty of evidence ]; and (3b) in adult ED patients (over the age of 18) presenting to the ED with CHS, we also suggest offering the use of topical capsaicin (in addition to usual care/serotonin antagonists, e.g., ondansetron) to help with symptom management [ very low certainty of evidence ].
Defining Benchmarks for Pelvic Exenteration Surgery
Brown, Kilian G. M. , Koh, Cherry , Sutton, Paul , Aguiar, Samuel , Bezerra, Tiago S. , Clouston, H.W., Desouza, Ashwin , Dozois, Eric J. , Ersryd, Amanda L., Frizelle, Frank , Funder, Jonas Amstrup , Garfinkle, Richard , Glyn, Tamara , Kanemitsu, Yukihide , Mens, David M , Palmer, Gabriella J., Pappou, Emmanouil P. , Quinn, Martha, Sahakitrungruang, Chucheep , Solbakken, Arne M. , Tiernan, Jim , Verhoef, Cornelis, Steffens, Daniel , Brown, Kilian G M , Solomon, Michael J. , García‐Aguilar, Julio , Heriot, Alexander G. , Kong, Chia Yew , Kristensen, Helle Ø , Malakorn, Songphol , Nilsson, Per Johan , Palmer, G. , Quyn, Aaron J. , Saklani, Avanish

Annals of Surgery | May 15, 2024 | Volume: 282 | Issue: 6 | Pages: 1118-1126

10.1097/sla.0000000000006348 | PMID 38747145 Get It

Objective: To establish globally applicable benchmark outcomes for pelvic exenteration (PE) in patients with locally advanced primary rectal cancer (LARC) and locally recurrent rectal cancer (LRRC), using outcomes achieved at highly specialised centres. Background: PE is established as the standard of care for selected patients with LARC and LRRC. There are currently no available benchmarks against which surgical performance in PE can be compared for audit and quality improvement. Methods: This international multicentre retrospective cohort study included patients undergoing PE for LARC or LRRC at 16 highly experienced centres between 2018 and 2023. Ten outcome benchmarks were established in a lower-risk subgroup. Benchmarks were defined by the 75th percentile of the results achieved at the individual centres. Results: Seven hundred sixty-three patients underwent PE, of which 464 patients (61%) had LARCs and 299 (39%) had LRRCs. Five hundred forty-four patients (71%) who met predefined lower-risk criteria formed the benchmark cohort. For patients with LARC, the calculated benchmark threshold for major complication rate was ≤44%; Comprehensive Complication Index: ≤30.2; 30-day mortality rate: 0%; 90-day mortality rate: ≤4.3%; R0 resection rate: ≥79%. For patients with LRRC, the calculated benchmark threshold for major complication rate was ≤53%; Comprehensive Complication Index: ≤34.1; 30-day mortality rate: 0%; 90-day mortality rate: ≤6%; R0 resection rate: ≥77%. Conclusions: The reported benchmarks for PE in patients with LARC and LRRC represent the best available care for this patient group globally and can be used for rigorous assessment of surgical quality and to facilitate quality improvement initiatives at international exenteration centres.
I-03 Dysregulation of T helper-type cytokines and interferons appear during early systemic lupus erythematosus pathogenesis and contribute to clinical disease development
Keith, Michael P. , Harley, John B., Munroe, Melissa E. , Lu, Rufei , Slight-Webb, Samantha R , Guthridge, Joel M. , Niewold, Timothy B. , Tsokos, George C. , James, Judith A.

Interferons | May 14, 2024 | Volume: No volume available | Issue: No issue available | Pages: A35.1-A35

10.1136/lupus-2016-000179.68 Get It

GG-06 Single cell gene expression studies in lupus patient monocytes reveal novel patterns reflecting disease activity, interferon, and medical treatment
Jin, Zhongbo , Jensen, Mark A, Dorschner, Jessica M., Vsetecka, Danielle, Amin, Shreyasee , Ernste, Floranne C. , Osborn, Thomas G. , Moder, Kevin G., Chowdhary, Vaidehi , Fan, Wei, Jensen, Mark A, Makol, Ashima , Niewold, Timothy B.

Genetics, Genomics and Epigenetics | May 14, 2024 | Volume: No volume available | Issue: No issue available | Pages: A30.1-A30

10.1136/lupus-2016-000179.58 Get It

Midbrain dopaminergic degeneration differentially modulates primary motor cortex activity and motor behavior in hemi-parkinsonian rats.
Seethaler, Julian, Wang, Shaohua , Lujan, Wendy D., Silvernail, Jodi L., Carter, Rickey E. , Chang, Su-Youne , Luján, J. Luis , Carter, Rickey E , Boschen, Suelen L.

No container title available | May 14, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4365911/v1 | PMID 38798359 Get It

Abstract Parkinson’s disease (PD) is marked by degeneration in the nigrostriatal dopaminergic pathway, affecting motor control via complex changes in the cortico-basal ganglia-thalamic motor network, including the primary motor cortex (M1). The modulation of M1 neuronal activity by dopaminergic inputs, particularly from the ventral tegmental area (VTA) and substantia nigra pars compacta (SNc), plays a crucial role in PD pathophysiology. This study investigates how nigrostriatal dopaminergic degeneration influences M1 neuronal activity in rats using in vivo calcium imaging. Histological analysis confirmed dopaminergic lesion severity, with high lesion level rats showing significant motor deficits. Levodopa treatment improved fine motor abilities, particularly in high lesion level rats. Analysis of M1 calcium signals based on dopaminergic lesion severity revealed distinct M1 activity patterns. Animals with low dopaminergic lesion showed increased calcium events, while high lesion level rats exhibited decreased activity, partially restored by levodopa. These findings suggest that M1 activity is more sensitive to transient fluctuations in dopaminergic transmission, rather than to chronic high or low dopaminergic signaling. This study underscores the complex interplay between dopaminergic signaling and M1 neuronal activity in PD symptoms development. Further research integrating behavioral and calcium imaging data can elucidate mechanisms underlying motor deficits and therapeutic responses in PD.
Optimizing pediatric periprocedural pain management part I—Evolving ethics and topical anesthetics
Henkel, Emily , Haller, Courtney N. , Diaz, Lucia Z., Ricles, Victoria , Grossman, Ashley V. Wong, Krakowski, Andrew C. , Wong Grossman, Ashley V, Nemergut, Michael E. , Grossman, Ashley Wong

Pediatric Dermatology | May 14, 2024 | Volume: 41 | Issue: 4 | Pages: 577-587

10.1111/pde.15635 | PMID 38743586 Get It

AbstractPediatric procedure‐related pain management is often incompletely understood, inadequately addressed, and critical in influencing a child's lifelong relationship with the larger health care community. We highlight the evolution of ethics and expectations around optimizing periprocedural pain management as a fundamental human right. We investigate the state‐of‐the‐art of topical anesthetics, reviewing their mechanisms of action and providing comparisons of their relative safety and efficacy data to help guide clinical selection. In total, this two‐part review offers a combination of conventional approaches and innovative techniques that should be used multimodally—in series and in parallel—to help optimize pain management and provide alternatives to sedation medication and general anesthesia.